GlobeNewswire Inc.··SanofiSanofi's Nuvaxovid Outperforms Moderna mRNA Vaccine in Tolerability Study
Sanofi's Nuvaxovid shows 50% fewer severe side effects than Moderna's mRNA vaccine in clinical trial, with patients twice as likely to choose it again.
SNYMRNAclinical trialCOVID-19 vaccine